Futura Medical Share Discussion Threads

[lbo] 16/3/2023 19:20

Even Trinity Research who are paid by Futura has contradicted the rampers and had to openly admit the hypothesised effects 'believes' to be happening by Futura are 'disputed'https://www.discovermagazine.com/health/the-erection-of-a-placeboThere is no evidence for the evaporative mode of action from the clinical trials. To show that the evaporation is what makes MED3000 work, you'd need to compare it to a non-evaporative gelhttps://www.ftc.gov/system/files/documents/public_statements/996984/p114505_otc_homeopathic_drug_enforcement_policy_statement.pdfProof is what separates an effect new to science from a swindle . . . . If a condition responds to treatment, then selling a placebo as if it had therapeutic effect directly injures the consumer. FTC v. QT, Inc.Trinity also admitted no mechanism of action has to be even shown to just get a low class medical device registered.But it does need to be shown and proven to substantiate its marketing claims of having any effect beyond a placebo or even arousal gel with the same alcohol, water, glycol and carbomer ingredients or fall foul of the FTC, ASA and the Courts.Trinity research:Presumably the effect is comparable to the cold-induced vasodilation (CIVD) that occurs with extremities such as toes and fingers. Despite being a well-known effect, the mechanisms of CIVD are still disputed, but the pathways involved could well be similar. Interestingly, the precise mechanism of action does not need to be elucidated for the regulators to be comfortable for a product to be approved as a medical deviceâââ€

[lbo] 16/3/2023 16:45

It took Joe some time to respond as a multi-ID ramper! All very sad indeed!

JoeStalin - 30 Sep 2019 - 10:07:37 - 5937 of 10774
FUTURA a winner for 2015 - says it all!


JoeStalin - 18 Jul 2018 - 09:00:46 - 4354 of 10775
'jam tomorrow' is a very easy promise to make.


JoeStalin - 22 Jun 2018 - 14:12:24 - 4288 of 10775
What's another year after all?
At FUM, time is measured in decades.


JoeStalin - 25 Apr 2018 - 16:07:34 - 4147 of 10775
There seems to be an unlimited number of ways of saying "Jam tomorrow".


JoeStalin - 21 Mar 2018 - 13:50:44 - 3985 of 10775
A lifestyle company, but not for the shareholders.

[joestalin] 16/3/2023 16:44

Only 5 minutes to respond to that one. All very sad.

[lbo] 16/3/2023 15:19

How many people die a year from alcohol related deaths? Or obesity related deaths? Both alcohol and obesity can also be an underlying cause of Erectile dysfunction. The use of a placebo gel will not deal with the underlying cause of the problem eg heavy drinking or untreated high blood pressure.

If anything placebos based on deception will just divert men from getting appropriate diagnosis of the real underlying cause and making more effective lifestyle changes.

An estimated 95,000 people (approximately 68,000 men and 27,000 women) die from alcohol-related causes annually




Erectile dysfunction is a common one, and can stem from several different health issues, including mental health concerns like anxiety, depression, and stress; health conditions such as heart disease, diabetes, obesity, and high cholesterol; and lifestyle factors like smoking, drinking alcohol, and lack of exercise.









Heart and circulatory deaths attributed to excess weight and obesity total around 31,000 every year in the UK, our new analysis reveals.

This is equivalent to around 85 deaths each day from heart and circulatory diseases which are attributable to a BMI (body mass index) of 25 or more, such as a heart attack or stroke. This is similar to the proportion of deaths from heart and circulatory diseases attributed to smoking underlining the huge toll that excess weight takes on the nations health.

[petroc] 16/3/2023 14:39

The multi-ID stock basher (aka LiamBooth, Leveraged, Citygirl, sbgae, LBO8 et al) is making contradictory claims to the results found in two clinical tests and a home use trial. The vast majority of users confirmed that Eroxon works. LiarBO can't show a single piece of evidence that shows otherwise, which is why he has to use spurious and unrelated links in an attempt to tar Eroxon.

[lbo] 16/3/2023 13:57

Especially seeing it in 2023 and still posting on ‘In FUTURA a winner for 2015’!!! ROFLMAO

JoeStalin - 30 Sep 2019 - 10:07:37 - 5937 of 10774
FUTURA a winner for 2015 - says it all!


JoeStalin - 18 Jul 2018 - 09:00:46 - 4354 of 10775
'jam tomorrow' is a very easy promise to make.


JoeStalin - 22 Jun 2018 - 14:12:24 - 4288 of 10775
What's another year after all?
At FUM, time is measured in decades.


JoeStalin - 25 Apr 2018 - 16:07:34 - 4147 of 10775
There seems to be an unlimited number of ways of saying "Jam tomorrow".


JoeStalin - 21 Mar 2018 - 13:50:44 - 3985 of 10775
A lifestyle company, but not for the shareholders.


JoeStalin - 22 Jan 2018 - 11:16:41 - 3640 of 17304

Only a clown thinks selling a few packs at all makes for a business.



Here's a startling fact: between 80% and 90% of new product launches fail, according to multiple studies including Harvard Business Review. Each year, more than 30,000 new products hit the market, from companies large and small, and year after year, history is littered with dead carcasses



Research at the Ehrenberg-Bass Institute shows new product launches can be a risky undertaking for brand owners. Investigating 83,719 new product introductions over an eight-year period, the research finds around one in four new products failed to survive one year after launch. This failure rate increased to around 40% two years after launch.



Why Most Product Launches Fail

[joestalin] 16/3/2023 13:36

It is sad to see.

[lbo] 16/3/2023 13:20

‘˜Eroxon was the placebo used in FM57’

So there is an admission that FM57 was designed and set up to study ‘another product’ Med2005!



If an advertiser expressly states or implicitly suggests a certain level of scientific evidence exists, it must have at least that level of evidence. So, statements like clinically proven or scientifically shown" require at least one or more clinical trials to support the claim. Additionally, an advertiser should not suggest a clinical trial has been conducted on the product if the study relied upon was conducted on a single ingredient or on another product. In such cases, the claim must be appropriately qualified to make the subject of the clinical trial clear

the ‘gold standard’ is a well-designed, double-blinded, placebo-controlled clinical trial appropriately conducted on the actual product. FTC has often required this standard in consent decrees, requiring two such studies for future claims made by companies governed by such decrees. Of course, these studies do not come cheaply, and most companies have not conducted such a study



In each of the six cases filed, FTC alleged that the companies not only lacked scientific substantiation for their claims regarding the health benefits of their CBD/CBG products, but also falsely represented that their claims were either scientifically proven or had been confirmed by the U.S. government.

Under the proposed orders settling FTC complaints in each of these cases, the companies and their owners are prohibited from making prevention, treatment, or safety claims similar to the ones the companies made about their products about any dietary supplements, foods, and drugs unless they have the human clinical testing to substantiate such claims, and are required to have competent and reliable scientific evidence for any other health-related product claims. Specifically, the testing must be: (1) randomized, double-blind, and placebo-controlled; and (2) conducted by researchers qualified by training and experience to conduct such testing. All of the companies must also notify consumers of the Commission’s order, and all but one of the companies will also be required to pay monetary judgments




When making health-related claims, courts have consistently held that an advertiser must have a reasonable basis to make the claim at issue. This standard is satisfied where the advertiser possesses competent and reliable scientific evidence supporting the claim (citing Sterling Drug, Inc. v. FTC, 741 F.2d 1146 [9th Cir. 1984]). After reviewing the testimony of several experts at trial, Magistrate Denlow concluded that when an advertiser makes a medical, health-related claim it must possess a well-conducted, placebo controlled, randomized, double-blinded study, the gold standard. (Citing FTC v. SlimAmerica, Inc., 77 F. Supp. 2d 1263 [S.D. FLA].) Any lower level of evidence would be deficient.

[lbo] 16/3/2023 13:11

And yet again just more false and misleading claims that you cannot substantiate with any non deficient evidence!

I note for someone who supposedly has so much to say about ‘ lying and deceiving’ . You have nothing to say about the ‘bias and fraud’ yourself have proven regarding Eroxon?.The UK HCP website that was provided by you says:

˜when assessed against internationally accepted criteria for clinical effectiveness (Rosen and Araujo) the efficacy of Eroxon exceeded the minimal clinically important difference’

And the HCP Brochure on the same website references the specific study ‘Minimal clinically Important Difference Rosen et al 2011’

But its clear in that study that the MCID criteria were estimated based on just regular adequately controlled and blinded oral only ED studies!

The Rosen study also clearly states in its limitations the results have not been replicated in ‘non pharmacologic studies’!!!

Why kind of ‘deceiving’ is that? Oh dear!

So they are clearly not internationally accepted criteria for ‘non pharmacologi studies’. Like a medical device gel study FM71. Whiich was totally uncontrolled, unblinded and prone to bias and therefore known to have much higher placebo effect then oral pharmacologic placebos in adequately controlled and blinded studies.

So now its been poven that some ‘deceiving’ is occurring wihen the inappropriate MCID comparison is being used in marketing to HCPs to make a indirect cross comparison to non regular inadequately blinded medical device gel studies.



MCIDs were estimated using data from 17 randomized, double-blind, placebo-controlled, parallel-group clinical trials of the phosphodiesterase type 5 inhibitor

limitations

Current analyses were based on 17 clinical trials of tadalafil. Results need to be replicated in studies using other PDE5-Is or in nonpharmacologic intervention studies.